Company profile
Voyant Bio
Novel biologics to overcome resistance to cancer immunotherapy.
- Industry
- Biotechnology Research
- Employees
- 6
- Founded
- 2023
Voyant Bio company summary
Voyant Bio is a company in the Biotechnology Research industry, founded in 2023. On LinkedIn the company has around 6 employees. Its listed specialties include scrnaseq, genomics, drug discovery, AI, ML.
What technology does Voyant Bio use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Voyant Bio
Over 80% of cancer patients fail to respond to immunotherapy because current approaches target only a single pathway—missing the complex, multi-pathway interactions between immune cells within tumors. At Voyant, we’ve developed the first AI-guided, spatially differentiated microscopy platform to reveal these hidden immune interactions that drive resistance to treatment across multiple cancer types. Using patient-derived tumor resections, our platform identifies novel immune cell interaction targets with clinical relevance. One such discovery—a novel 3-way immune interaction linked to PD-1 resistance—was recently published in Nature. We’re now advancing a novel therapeutic in a $100B+ market and are currently raising a $3M pre-seed to complete ex vivo studies and expand our immune cell interaction atlas.
Specialties
Compare companies similar to Voyant Bio
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Voyant Bio voyant-bio.com | Biotechnology Research | 6 | 2023 | - |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Voyant Bio
What does Voyant Bio do?
Over 80% of cancer patients fail to respond to immunotherapy because current approaches target only a single pathway—missing the complex, multi-pathway interactions between immune cells within tumors. At Voyant, we’ve developed the first AI-guided, spatially differentiated microscopy platform to reveal these hidden immune interactions that drive resistance to treatment across multiple cancer types. Using patient-derived tumor resections, our platform identifies novel immune cell interaction targets with clinical relevance. One such discovery—a novel 3-way immune interaction linked to PD-1 resistance—was recently published in Nature. We’re now advancing a novel therapeutic in a $100B+ market and are currently raising a $3M pre-seed to complete ex vivo studies and expand our immune cell interaction atlas.
How many employees does Voyant Bio have?
Voyant Bio has around 6 employees on LinkedIn.
When was Voyant Bio founded?
Voyant Bio was founded in 2023.
Build a lead list from companies like Voyant Bio
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.